Genprex

Tagged: Shareholder Letter

Genprex Issues Shareholder Letter and Provides 2022 Corporate Update

Company achieves major milestones in clinical development programs in 2022

Patient treatment in Acclaim-2 clinical trial commences

Read More

Genprex Issues Shareholder Letter and Provides Corporate Update

Major milestones achieved in advancing gene therapies for lung cancer and diabetes

Read More